Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
Astex Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Merck Sharp & Dohme LLC
University of North Carolina, Chapel Hill
Seagen Inc.
Seagen Inc.
AVEO Pharmaceuticals, Inc.